Comparative Pharmacology
Head-to-head clinical analysis: CUVRIOR versus PENTETATE CALCIUM TRISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUVRIOR versus PENTETATE CALCIUM TRISODIUM.
CUVRIOR vs PENTETATE CALCIUM TRISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.
Pentetate calcium trisodium is a chelating agent that forms stable complexes with divalent and trivalent heavy metal ions, such as plutonium, americium, and curium. It enhances the urinary elimination of these metals by increasing the rate of dissociation from tissues and promoting renal excretion.
300 mg subcutaneously once daily.
1 g (one vial) intravenously over 1 hour once daily for up to 5 days.
None Documented
None Documented
Terminal elimination half-life is approximately 0.9–1.5 hours; however, pharmacodynamic effects (copper mobilization) persist for 24–48 hours.
Terminal elimination half-life is approximately 0.6-0.8 hours in patients with normal renal function.
Primarily hepatobiliary; unchanged drug and metabolites excreted in feces. Renal elimination accounts for <5% of the administered dose.
Primarily renal elimination via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours.
Category C
Category C
Chelating Agent
Chelating Agent